GlobeNews Wire

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed in patients with LADData support…

3 weeks ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to…

3 weeks ago

Fluent Inc. Subsidiary Trevant Launches as Creator Marketing Agency Built on Performance Discipline

Trevant pairs creator-native expertise with the measurement and scale infrastructure AdParlor spent a decade building June 02, 2026 08:03 ET…

3 weeks ago

Scality and Biomemory partner to pioneer ultra-secure, DNA-based data archives with 150-year retention

SAN FRANCISCO and BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Scality, a global leader in data infrastructure software for AI-era…

3 weeks ago

Rocket Doctor AI Announces Strong Q1 Momentum Driven by U.S. Expansion, New Payer Contracts and Platform Growth

Continued organic quarter over quarter revenue growth to $737KEarnings per share for Q1, 2026: ($0.05) per share.Announced further signed in-network…

3 weeks ago

Philips announces exchange ratio for 2025 dividend

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for the dividend for the year…

3 weeks ago

FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate

Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvalsAppointment strengthens confidence…

3 weeks ago

Nanobiotix Joins the Euronext Tech Leaders Index

PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a…

3 weeks ago

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenstrm Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

June 01, 2026 08:05 ET  | Source: Cellectar Biosciences, Inc. Approximately 80% Major Response Rate and Duration of Response Exceeding…

3 weeks ago

LifeMD Appoints Umesh Sripad as Chief Technology Officer

Seasoned Technology Executive Brings More Than Two Decades of Large-Scale Digital Transformation Experience to Support LifeMD’s Next Phase of Growth…

3 weeks ago